Market revenue in 2023 | USD 200.8 million |
Market revenue in 2030 | USD 262.2 million |
Growth rate | 3.9% (CAGR from 2023 to 2030) |
Largest segment | Cannabis/marijuana |
Fastest growing segment | Cannabis/Marijuana |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Other Drug Types |
Key market players worldwide | Quest Diagnostics Inc, Abbott Laboratories, Clinical Reference Laboratory, Cordant Health Solutions, ZeOmega, Psychemedics Corp, Millennium HealthCare Inc, Mayo Clinic, Precision Diagnostics, LGC Group, Labcorp Drug Development, Legacy Medical, Drugscan, USDTL |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug of abuse testing services market will help companies and investors design strategic landscapes.
Cannabis/marijuana was the largest segment with a revenue share of 24.25% in 2023. Horizon Databook has segmented the France drug of abuse testing services market based on alcohol, cannabis/marijuana, cocaine, opioids, amphetamine & methamphetamine, lsd, other drug types covering the revenue growth of each sub-segment from 2018 to 2030.
In France, workplace drug testing is allowed, but only during employment; tests cannot be carried out before hiring. In addition, routine drug screening tests are not permitted in the workplace. However, drug testing can be considered as per the occupation (e.g., a position in the transportation or security industries) and the employee is informed about the screening process.
Furthermore, in 2017 French government increased the use of roadside saliva testing to reduce cases of driving under the influence. The increase in government initiatives to boost drug abuse testing is anticipated to propel the demand for testing services.
Moreover, as per data published by EMCDDA, in 2016, around 21.8% and 3.2% of young adults (18 to 34 years) in France consumed cannabis and cocaine, respectively. Such a high prevalence of drug abuse is anticipated to create lucrative opportunities for market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the France drug of abuse testing services market , including forecasts for subscribers. This country databook contains high-level insights into France drug of abuse testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account